Liminatus Pharma, Inc.
LIMNLiminatus Pharma is a pre-clinical stage biopharmaceutical company focused on developing novel cancer therapies that leverage the body's immune system.
Earnings
Next report
Date not yet announcedCompetitors
By market cap
By revenue growth
Profile
Liminatus Pharma is a pre-clinical stage biopharmaceutical company focused on developing novel cancer therapies that leverage the body's immune system. Its primary value proposition is a next-generation CD47 checkpoint inhibitor designed to target solid tumors while avoiding the common side effects of anemia and thrombocytopenia associated with earlier CD47 treatments. The company aims to establish a leadership position in immuno-oncology through both internal development and strategic in-licensing of differentiated therapeutic assets.
Liminatus is a pre-clinical developer seeking to differentiate itself through a next-generation CD47 antibody that avoids red blood cell binding, a major limitation of first-generation competitors.
FAQ
- What is Liminatus Pharma, Inc.'s market cap?
- Liminatus Pharma, Inc. (LIMN) has a market capitalization of $5.9M and trades on NASDAQ.
- Who are Liminatus Pharma, Inc.'s competitors?
- Liminatus Pharma, Inc.'s key competitors include Bristol-Myers Squibb, Regeneron, Pfizer, and others. These companies compete in similar markets and product categories.
- Who does Liminatus Pharma, Inc. partner with?
- Liminatus Pharma, Inc.'s notable partners include InnoBation Bio Co. Ltd., GenScript ProBio, Charles River Laboratories, and others.
- What subsidiaries does Liminatus Pharma, Inc. have?
- Liminatus Pharma, Inc.'s subsidiaries include Liminatus Pharma, LLC.
- Where is Liminatus Pharma, Inc. headquartered?
- Liminatus Pharma, Inc. is headquartered in United States of America. It has been publicly traded since 2025.